{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-029969","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.852371+00:00","generated_at":"2026-06-05T05:52:12.475584+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Celldex prices upsized $400M common stock offering at $47/share, net proceeds ~$376M","bullets":["Priced public offering of 8,520,000 shares at $47.00 per share; upsized from initial $250M to $400M.","Net proceeds expected ~$376.2M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to an additional 1,278,000 shares.","Proceeds to fund clinical/preclinical development of barzolvolimab, bispecific antibody platform, and pipeline.","Offering expected to close on or about March 5, 2024, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-029969","json":"https://secwatch.observer/filing/0001104659-24-029969.json","markdown":"https://secwatch.observer/filing/0001104659-24-029969.md","text":"https://secwatch.observer/filing/0001104659-24-029969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000110465924029969/0001104659-24-029969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000110465924029969/tm247553d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:52:12.475584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6339979b5f9ba481a66125f0dcec3b20571b10e0","claim":"Celldex Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Cowen and Company, LLC valued at approximately $376.2 million (effective 2024-02-29).","evidence_excerpt":"On February 29, 2024, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Cowen and Company, LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 8,520,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $47.00 per share (the “Offering”). The net proceeds to the Company from the Offering are expected to be approximately $376.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744218/000110465924029969/0001104659-24-029969-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Leerink Partners LLC and Cowen and Company, LLC"},{"label":"Value","value":"approximately $376.2 million"},{"label":"Effective","value":"2024-02-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}